CA3133610A1 - Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function - Google Patents

Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function Download PDF

Info

Publication number
CA3133610A1
CA3133610A1 CA3133610A CA3133610A CA3133610A1 CA 3133610 A1 CA3133610 A1 CA 3133610A1 CA 3133610 A CA3133610 A CA 3133610A CA 3133610 A CA3133610 A CA 3133610A CA 3133610 A1 CA3133610 A1 CA 3133610A1
Authority
CA
Canada
Prior art keywords
seq
sequence
blood
brain barrier
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133610A
Other languages
English (en)
French (fr)
Inventor
Yukio Takeshita
Takashi Kanda
Kenichi Serizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CA3133610A1 publication Critical patent/CA3133610A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3133610A 2019-03-29 2020-02-17 Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function Pending CA3133610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-068693 2019-03-29
JP2019068693 2019-03-29
PCT/JP2020/005965 WO2020202839A1 (ja) 2019-03-29 2020-02-17 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤

Publications (1)

Publication Number Publication Date
CA3133610A1 true CA3133610A1 (en) 2020-10-08

Family

ID=72667972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133610A Pending CA3133610A1 (en) 2019-03-29 2020-02-17 Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function

Country Status (12)

Country Link
US (1) US20220220210A1 (https=)
EP (1) EP3949989A4 (https=)
JP (2) JPWO2020202839A1 (https=)
KR (1) KR20210144795A (https=)
CN (1) CN113660951A (https=)
AU (1) AU2020255449A1 (https=)
BR (1) BR112021017702A2 (https=)
CA (1) CA3133610A1 (https=)
IL (1) IL286716A (https=)
MX (1) MX2021011464A (https=)
TW (1) TWI859192B (https=)
WO (1) WO2020202839A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466018A4 (en) * 2022-01-19 2026-03-25 Chugai Pharmaceutical Co Ltd TREATMENT OF AUTOIMMUNE ENCEPHALITIS WITH SATRALIZUMAB

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
EP4413998A4 (en) * 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
KR101680906B1 (ko) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
SI2315780T1 (sl) * 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4809930B2 (ja) 2009-03-19 2011-11-09 中外製薬株式会社 関節リウマチ治療剤
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2012322721B2 (en) * 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
EP3185004A4 (en) * 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US11447752B2 (en) 2016-04-15 2022-09-20 Yamaguchi University In vitro model for blood-brain barrier and method for producing in vitro model for blood-brain barrier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466018A4 (en) * 2022-01-19 2026-03-25 Chugai Pharmaceutical Co Ltd TREATMENT OF AUTOIMMUNE ENCEPHALITIS WITH SATRALIZUMAB

Also Published As

Publication number Publication date
TW202102540A (zh) 2021-01-16
TWI859192B (zh) 2024-10-21
WO2020202839A1 (ja) 2020-10-08
EP3949989A4 (en) 2022-12-14
JP2024102154A (ja) 2024-07-30
CN113660951A (zh) 2021-11-16
AU2020255449A1 (en) 2021-10-07
JPWO2020202839A1 (https=) 2020-10-08
BR112021017702A2 (pt) 2021-11-16
MX2021011464A (es) 2021-10-22
IL286716A (en) 2021-12-01
EP3949989A1 (en) 2022-02-09
US20220220210A1 (en) 2022-07-14
KR20210144795A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
EP3949989A1 (en) Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
EP3311824B1 (en) Cd47 targeted therapies for the treatment of infectious disease
JP2019031545A (ja) 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP5834004B2 (ja) ループス治療のための方法および組成物
KR20090076960A (ko) 용혈성 빈혈 치료법
EP3554543A2 (en) Stable aqueous anti-c5 antibody composition
KR102614764B1 (ko) 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
US20240109977A1 (en) Anti-cd38 antibodies and their uses
Stoltz et al. Ethanol suppression of the functional state of polymorphonuclear leukocytes obtained from uninfected and simian immunodeficiency virus infected rhesus macaques
Spry Alterations in blood eosinophil morphology, binding capacity for complexed IgG and kinetics in patients with tropical (filarial) eosinophilia
JP5583575B2 (ja) 感染症と関連炎症過程の治療のためのタンパク質生成物
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
HK40056582A (en) Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
US20230355815A1 (en) Active delivery of radiotracers across the blood brain barrier
AU2006285306A1 (en) Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
SK12212003A3 (sk) CD25 väzbová molekula na použitie na prevenciu alebo liečenie niektorých ochorení u pacientov rezistentných na liečbu steroidmi
KR102575322B1 (ko) 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
US20190209680A1 (en) Treatment of acute liver failure
AU2020267329B2 (en) Treatment of brain ischemia-reperfusion injury
CN118662628A (zh) 抗ox40抗体在治疗炎症或免疫性疾病中的应用
US20230391857A1 (en) Methods of treating infections by blocking pathogen mimics of cd47
WO2025257810A1 (en) Suppression of neurodegenerative diseases by single domain antibody
CN118451099A (zh) 血脑屏障通透性融合蛋白以及其用途
TW202607019A (zh) 通過單域抗體對神經退化性疾病之抑制
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251231

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251231

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209